Curatis Holding AG (SWX:CURN)

Switzerland · Delayed Price · Currency is CHF

23.00

-0.90 (-3.77%)

Jul 14, 2026, 5:31 PM CET

111.01% (1Y)

Market Cap	121.93M +105.2%
Revenue (ttm)	10.80M +56.6%
Net Income	-1.42M
EPS	-0.28
Shares Out	5.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,138
Open	22.40
Previous Close	23.90
Day's Range	22.40 - 23.90
52-Week Range	10.05 - 27.90
Beta	-0.77
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 21, 2026

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collage... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 9

Stock Exchange SIX Swiss Exchange

Ticker Symbol CURN

Full Company Profile

Financial Performance

In 2025, Curatis Holding AG's revenue was 10.80 million, an increase of 56.61% compared to the previous year's 6.90 million. Losses were -1.42 million, -67.41% less than in 2024.

Financial Statements